

September 2019 ~ Resource #350932

## Anticipated Availability of First-Time Generics

—To help explain the benefits of generic drugs to your patients,  
the FDA has patient education materials available at <https://www.fda.gov/drugs/generic-drugs/patient-education> —

Brand <sup>a</sup> (Manufacturer)	Generic Name	Generic Manufacturer(s) <sup>b,1</sup>	Anticipated Availability <sup>c</sup>
<i>Acanya</i> (Valeant)	Benzoyl peroxide 2.5%/ Clindamycin phosphate 1.2%	Teva	Generic now available
<i>Cuprimine</i> (Bausch Health)	Penicillamine capsule	Amerigen, Teva	Generic now available
<i>Delzicol</i> (Warner Chilcott)	Mesalamine delayed-release capsule	Teva	Generic now available
<i>Diclegis</i> (Duchesnay)	Doxylamine/Pyridoxine	Teva	Generic now available
<i>Exjade</i> (Novartis)	Deferasirox tablets for oral suspension	Teva	Generic now available
<i>Fareston</i> (Kyowa Kirin)	Toremifene	Rising (EirGen Pharma Limited)	Generic now available
<i>Faslodex</i> (AstraZeneca)	Fulvestrant	Sandoz	Generic now available
<i>Firazyr</i> (Shire Orphan Therapies)	Icatibant	Teva	Generic now available
<i>Gablofen</i> (Piramal)	Baclofen 1 mg/mL single dose vial	Mylan Institutional	Generic now available
<i>Hemabate</i> (Pharmacia & Upjohn)	Carboprost tromethamine	Dr. Reddy's	Generic now available
<i>Letairis</i> (Gilead)	Ambrisentan	Cipla, Mylan, Par, Sigmapharm, Sun, Teva, Zydus	Generic now available
<i>Lexiva</i> (Viv)	Fosamprenavir	Mylan	Generic now available

More . . .

<b>Brand<sup>a</sup> (Manufacturer)</b>	<b>Generic Name</b>	<b>Generic Manufacturer(s)<sup>b,1</sup></b>	<b>Anticipated Availability<sup>c</sup></b>
<i>Lotemax</i> (Bausch & Lomb)	Loteprednol ophthalmic suspension	Hi-tech	Generic now available
<i>Lyrica</i> (PF Prism CV)	Pregabalin capsule	Alembic, Amneal, Ascend (Alkem), Cipla (InvaGen), Dr. Reddy's, Exelan (InvaGen), Major (Rising), Novadoz (MSN), Rising, Sciegen, Teva	Generic now available
<i>Lyrica</i> (PF Prism CV)	Pregabalin oral solution	Ascend (Alkem)	Generic now available
<i>Mestinon</i> (Bausch)	Pyridostigmine bromide syrup	Novitium	Generic now available
<i>Mifeprex</i> (Danco)	Mifepristone	Genbiopro	Generic now available
<i>Minivelle</i> (Noven)	Estradiol transdermal patch	Mylan	Generic now available
<i>Naftin</i> (Sebela Ireland)	Naftifine gel 1%	Impax (Amneal, Tolmar)	Generic now available
<i>Nebupent</i> (Fresenius Kabi)	Pentamidine 300 mg powder for inhalation solution	Seton	Generic now available
<i>Precedex</i> (Hospira)	Dexmedetomidine 4 mcg/mL in normal saline (50 mL, 100 mL)	Baxter, Fresenius Kabi	Generic now available
<i>Precedex</i> (Hospira)	Dexmedetomidine 4 mcg/mL in normal saline (20 mL)	Fresenius Kabi	Generic now available
<i>Ranexa</i> (Gilead)	Ranolazine	Ajanta, Golden State (ScieGen), Lupin, Ranbaxy (Sun), ScieGen, Teva	Generic now available
<i>Rapamune</i> (PF Prism CV)	Sirolimus 1 mg/mL oral solution	Vistapharm (Novitium)	Generic now available
<i>Remodulin</i> (United Therapeutics)	Treprostinil	Sandoz	Generic now available
<i>Renagel</i> (Genzyme)	Sevelamer hydrochloride	Glenmark	Generic now available
<i>Revatio</i> (Pfizer)	Sildenafil powder for oral suspension	Novitium	Generic now available

More...

<b>Brand<sup>a</sup> (Manufacturer)</b>	<b>Generic Name</b>	<b>Generic Manufacturer(s)<sup>b,1</sup></b>	<b>Anticipated Availability<sup>c</sup></b>
<i>Sabril</i> (Lundbeck)	Vigabatrin tablets	Teva	Generic now available
<i>Sensipar</i> (Amgen)	Cinacalcet	Ascend (Alkem), Aurobindo, Cipla, Mylan, Slate Run (Piramal), Strides Pharma, Teva	Generic now available
<i>Solodyn</i> (Medicis)	Minocycline 55, 80, 105 mg extended-release tablet	Ascend (Alkem) (80, 105 mg), Lupin (55 mg), Mylan (80, 105 mg), Teva (80, 105 mg)	Generic now available
<i>Sporanox</i> (Janssen)	Itraconazole oral solution	Amneal	Generic now available
<i>Suprane</i> (Baxter)	Desflurane	Sandoz (Shanghai Hengrui)	Generic now available
<i>Tarceva</i> (OSI)	Erlotinib	Mylan, Teva	Generic now available
<i>Tekturna</i> (Novartis)	Aliskiren	Par (Anchen)	Generic now available
<i>Tracleer</i> (Actelion)	Bosentan tablets	Amneal, Hikma (West-ward), Par, Sun, Teva, Zydus	Generic now available
<i>Uloric</i> (Takeda)	Febuxostat	Alembic, Mylan	Generic now available
<i>Valstar</i> (Endo)	Valrubicin	Leucadia (Custopharm)	Generic now available
<i>Vesicare</i> (Astellas)	Solifenacin succinate	Ajanta, Alembic, Alkem (Ascend), Amneal, Apotex (Qilu), AustarPharma (Jiangxi Boya Seehot), Breckenridge, Celltrion, Cipla, Glenmark, Golden State (Jiangxi Boya Seehot), Novadoz (MSN), Teva	Generic now available
<i>Zovirax</i> (Bausch)	Acyclovir 5% cream	Perrigo	Generic now available
<i>EpiPen Jr.</i> (Mylan)	Epinephrine	Teva	2019 <sup>18</sup>

More . . .

Brand <sup>a</sup> (Manufacturer)	Generic Name	Generic Manufacturer(s) <sup>b,1</sup>	Anticipated Availability <sup>c</sup>
<i>Herceptin</i> (Roche)	Trastuzumab	Celltrion/Teva ( <i>Herzuma</i> ; biosimilar <sup>i</sup> ), <sup>100</sup> Merck/Samsung Bioepis ( <i>Ontruzant</i> ; biosimilar <sup>i</sup> ), <sup>100</sup> Mylan ( <i>Ogivri</i> ; biosimilar <sup>i</sup> ), <sup>33</sup> Pfizer ( <i>Trazimera</i> , biosimilar <sup>i</sup> ) <sup>112</sup>	2019 <sup>33</sup>
<i>Restasis</i> (Allergan)	Cyclosporine ophthalmic emulsion	Akorn, <sup>f</sup> Mylan, <sup>f</sup> Teva <sup>f</sup>	2019 <sup>30</sup>
<i>Abstral</i> (Orexo)	Fentanyl sublingual tablet	Teva	September 2019 (or earlier) <sup>78</sup>
<i>Edluar</i> (Meda)	Zolpidem sublingual tablet	Mylan, Par	September 2019 (or earlier <sup>e</sup> ) <sup>154,155</sup>
<i>Factive</i> (Methapharm)	Gemifloxacin	Orchid	September 2019
<i>Treanda</i> (Teva)	Bendamustine 25 mg/vial and 100 mg/vial (powder)	Accord, Apotex, Breckinridge, Celerity, Glenmark, Hospira, InnoPharma, Mylan, Sagent, <sup>f,107</sup> Spectrum	November 2019 (or earlier) <sup>111</sup>
<i>Aptensio XR</i> (Rhodes)	Methylphenidate extended-release capsules	Teva	December 2019 (or earlier <sup>e</sup> ) <sup>94</sup>
<i>Byetta</i> (AstraZeneca)	Exenatide	Teva <sup>f,61</sup>	January 2020 (or earlier) <sup>61</sup>
<i>Daliresp</i> (AstraZeneca)	Roflumilast	Alkem, Apotex, <sup>h,72</sup> Breckenridge, Hetero, Micro Labs, MSN, Mylan, Prinston, Strides Pharma, Torrent	January 2020 (or later) <sup>156</sup>
<i>Jadenu</i> (Novartis)	Deferasirox tablet	Teva, Zydus	January 2020 <sup>142</sup>
<i>Noxafil</i> (Merck)	Posaconazole injection	Fresenius Kabi, Mylan, Par	January 2020 <sup>24</sup>
<i>Silenor</i> (Somaxon)	Doxepin tablet	Par, Zydus	January 2020 (or earlier) <sup>39</sup>
<i>Moxeza</i> (Alcon)	Moxifloxacin ophthalmic solution	Lupin, Teva	March 2020 (or earlier <sup>e</sup> ) <sup>6</sup>

More . . .

<b>Brand<sup>a</sup> (Manufacturer)</b>	<b>Generic Name</b>	<b>Generic Manufacturer(s)<sup>b,1</sup></b>	<b>Anticipated Availability<sup>c</sup></b>
<i>Zortress</i> (Novartis)	Everolimus	West-ward (Hikma)	March 2020
<i>Avandia</i> (GlaxoSmithKline)	Rosiglitazone	Dr. Reddy's, Hikma, Mylan, Roxane, Sandoz, Teva	April 2020
<i>Chantix</i> (Pfizer)	Varenicline	Apotex, Mylan, Teva	May 2020 (or earlier <sup>d</sup> ) <sup>49</sup>
<i>Desonate</i> (Bayer)	Desonide 0.05% gel	Teresina Holdings	August 2020 (or earlier <sup>d</sup> ) <sup>21</sup>
<i>Atripla</i> (Gilead)	Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate	Aurobindo, Cipla, Hetero, Macleods, Matrix	September 2020 <sup>24</sup>
<i>Truvada</i> (Gilead)	Emtricitabine/Tenofovir disoproxil fumarate tablet	Aurobindo, Cipla, Hetero, Lupin, <sup>f,25</sup> Matrix, Mylan, Strides Arcolab, Teva	September 2020 <sup>20</sup>
<i>Farxiga</i> (AstraZeneca)	Dapagliflozin	Alembic, Alkem, Apotex, Hetero, Inventia, Micro Labs, Sandoz, Sun, Teva	October 2020 <sup>164</sup>
<i>Kuvan</i> (BioMarin)	Sapropterin	Dr. Reddy's, Par, Sandoz	October 2020 (or earlier) <sup>47,161</sup>
<i>Kaletra</i> (Abbott)	Lopinavir/Ritonavir tablet	Aurobindo, Cipla, Hetero, Lannett, Macleods, Matrix, Mylan	November 2020 <sup>101</sup>
<i>Absorica</i> (Ranbaxy)	Isotretinoin	Teva <sup>f,88</sup>	December 2020 (or earlier) <sup>88</sup>
<i>Ofirmev</i> (Mallinckrodt)	Acetaminophen injection	Custopharm (Perrigo), Sandoz	December 2020 (or earlier) <sup>31</sup>
<i>Saphris</i> (Forest)	Asenapine	Alembic, Amneal, <sup>f,130</sup> Breckenridge, <sup>f,130</sup> Hikma <sup>f,130</sup>	December 2020 <sup>130</sup>
<i>Viibryd</i> (Forest)	Vilazodone	Accord, Alembic, Teva	2021 <sup>24</sup>
<i>Amitiza</i> (Sucampo)	Lubiprostone	Amneal, Anchen, <sup>f,115</sup> Dr. Reddy's, <sup>h,115</sup> Par <sup>f,115</sup>	January 2021 <sup>115</sup>
<i>Mycamine</i> (Astellas)	Micafungin	Apotex, Fresenius Kabi	January 2021 (or earlier <sup>e</sup> ) <sup>81,175</sup>
<i>Sutent</i> (Pfizer)	Sunitinib	Mylan	February 2021

More . . .

<b>Brand<sup>a</sup> (Manufacturer)</b>	<b>Generic Name</b>	<b>Generic Manufacturer(s)<sup>b,1</sup></b>	<b>Anticipated Availability<sup>c</sup></b>
<i>Zomig</i> (AstraZeneca)	Zolmitriptan nasal spray	Lannett <sup>f,165</sup>	May 2021
<i>Ferriprox</i> (Apopharma)	Deferiprone	Taro	June 2021 (or earlier <sup>e</sup> ) <sup>74</sup>
<i>Fycompa</i> (Eisai)	Perampanel	Accord, Teva, Taro	June 2021 <sup>122</sup>
<i>Perforomist</i> (Mylan)	Formoterol inhalation solution	Teva	June 2021
<i>Selzentry</i> (Pfizer)	Maraviroc	Hetero, Sandoz	August 2021 (or earlier <sup>d</sup> ) <sup>21</sup>
<i>Bystolic</i> (Forest)	Nebivolol	Hetero, <sup>f,67</sup> Micro Labs	September 2021 (or earlier) <sup>67</sup>
<i>Emtriva</i> (Gilead)	Emtricitabine capsule	Aurobindo, Cipla, Matrix, Micro Labs	September 2021 <sup>4</sup>
<i>Jevtana</i> (Sanofi Aventis)	Cabazitaxel	Accord, Apotex, BPI Labs, Breckenridge, Dr. Reddy's, <sup>h,121</sup> Fresenius Kabi, <sup>h,151</sup> Glenmark, <sup>h,121</sup> Mylan, Sandoz, Teva	September 2021 <sup>58</sup>
<i>Emend</i> (Merck)	Fosaprepitant injection	Fresenius Kabi, Lupin, MSN, Sagent, Sandoz	October 2021
<i>Brovana</i> (Sunovion)	Arformoterol	Cipla, Teva	November 2021 <sup>24</sup>
<i>Pradaxa</i> (Boehringer Ingelheim)	Dabigatran	Alembic, Glenmark, Hetero, <sup>h,44</sup> Mylan, <sup>f,3</sup> Teva	December 2021(or earlier <sup>d</sup> ) <sup>44</sup>
<i>Velcade</i> (Millennium)	Bortezomib	Accord, Apotex, Dr. Reddy's, Hospira, Mylan, Pharmascience, Qilu, Shilpa, Teva	January 2022 <sup>125</sup>
<i>Revlimid</i> (Celgene)	Lenalidomide	Allergan <sup>f,23</sup>	March 2022 <sup>23</sup>
<i>Vimpat</i> (UCB)	Lacosamide	Tablet: Accord, Alembic, Amneal, Aurobindo, Glenmark, MSN, Mylan, Sun, Teva Oral solution: Amneal, Apotex, Glenmark	March 2022 <sup>5</sup>

More . . .

<b>Brand<sup>a</sup> (Manufacturer)</b>	<b>Generic Name</b>	<b>Generic Manufacturer(s)<sup>b,1</sup></b>	<b>Anticipated Availability<sup>c</sup></b>
<i>Zipsor</i> (Assertio)	Diclofenac potassium liquid-filled capsule	Bionpharma, Teva <sup>f,95</sup>	March 2022 (or earlier) <sup>95</sup>
<i>Alimta</i> (Lilly)	Pemetrexed	Accord, Apotex, APP, Biocon, Dr. Reddy's, Hospira, Jiangsu Hansoh, Mylan, Qilu, Sun, Teva	May 2022
<i>Banzel</i> (Eisai)	Rufinamide	Tablet: Glenmark, Hetero, <sup>h,80</sup> Lupin, <sup>f,145</sup> West-Ward Suspension: Bionpharma, Hikma	May 2022 (or earlier) <sup>48</sup>
<i>Iressa</i> (AstraZeneca)	Gefitinib	Cipla	July 2022
<i>Janumet</i> (Merck)	Sitagliptin/Metformin	Apotex, Sandoz, Teva, Zydus	July 2022 <sup>124</sup>
<i>Janumet XR</i> (Merck)	Sitagliptin/Metformin extended-release tablet	Anchen, Teva	July 2022 <sup>124</sup>
<i>Januvia</i> (Merck)	Sitagliptin	Apotex, Mylan, Sandoz, Sun, Teva, Zydus	July 2022 <sup>124</sup>
<i>Toviaz</i> (Pfizer)	Fesoterodine extended-release tablet	Accord, Alembic, Amerigen, Amneal, Aurobindo, Dr. Reddy's, Impax, <sup>h,97</sup> Lupin, Mylan, <sup>f,63</sup> Sandoz, Sun, Teva, Torrent, Wockhardt, <sup>h,82</sup> Zydus	July 2022 (or earlier <sup>e</sup> ) <sup>11,63</sup>
<i>Afinitor</i> (Novartis)	Everolimus	Breckenridge, <sup>f,2</sup> Par, Roxane, <sup>h,148</sup> West-ward	August 2022 <sup>29</sup>
<i>Bethkis</i> (Chiesi)	Tobramycin inhalation solution	Teva	September 2022
<i>Folotyn</i> (Spectrum)	Pralatrexate	Teva	November 2022 <sup>149</sup>
<i>Epiduo Forte</i> (Galderma)	Adapalene 0.3%/Benzoyl peroxide 2.5%	Taro, Teva	December 2022 (or earlier <sup>e</sup> ) <sup>117</sup>
<i>Rayos</i> (Horizon)	Prednisone delayed-release tablet	Teva	December 2022 (or earlier) <sup>36</sup>
<i>Zioptan</i> (Oak)	Tafluprost	Sandoz	December 2022 <sup>170</sup>

More . . .

<b>Brand<sup>a</sup> (Manufacturer)</b>	<b>Generic Name</b>	<b>Generic Manufacturer(s)<sup>b,1</sup></b>	<b>Anticipated Availability<sup>c</sup></b>
<i>Cambia</i> (Depomed)	Diclofenac potassium oral solution 50 mg	Par	January 2023 <sup>24</sup>
<i>Humira</i> (AbbVie)	Adalimumab	Amgen (biosimilar <sup>i</sup> ), <sup>162</sup> Boehringer Ingelheim (biosimilar <sup>i</sup> ), <sup>26</sup> Fresenius Kabi (biosimilar <sup>i</sup> ), <sup>146</sup> Mylan (biosimilar <sup>i</sup> ), <sup>171</sup> Samsung Bioepis (biosimilar <sup>i</sup> ), <sup>162</sup> Sandoz (biosimilar <sup>i</sup> ) <sup>167</sup>	January 2023 <sup>162</sup>
<i>Trokendi XR</i> (Supernus)	Topiramate extended-release capsule	Zydus	January 2023 <sup>118</sup>
<i>Latuda</i> (Sunovion)	Lurasidone	Accord, Amneal, Aurobindo, Emcure, First Time U.S. Generics, InvaGen, Lupin, MSN, Par, Piramal, Sun, Teva, Torrent, Zydus	February 2023 <sup>131</sup>
<i>Vimovo</i> (Horizon)	Naproxen/Esomeprazole magnesium delayed-release tablet	Anchen, Dr. Reddy's, Lupin, <sup>f,77</sup> Mylan	February 2023 <sup>77</sup>
<i>Vyvanse</i> (Shire)	Lisdexamfetamine	Amneal, Mylan, Roxane, Sandoz, Teva	February 2023 <sup>55</sup>
<i>Afinitor Disperz</i> (Novartis)	Everolimus	Mylan	March 2023 (or earlier <sup>e</sup> ) <sup>10</sup>
<i>Aubagio</i> (Sanofi)	Teriflunomide	Accord, Alembic, Alvogen, Glenmark, MSN, Mylan, <sup>h,174</sup> Sandoz, Torrent	March 2023 <sup>24</sup>
<i>Suprep</i> (Braintree)	Magnesium sulfate anhydrous, potassium sulfate, sodium sulfate	Breckenridge, Lupin (Novel), Paddock (Perrigo), Taro	March 2023
<i>Edurant</i> (Janssen)	Rilpivirine	Strides Arcolab	April 2023 <sup>65</sup>
<i>Livalo</i> (Kowa)	Pitavastatin magnesium	Amneal, Aurobindo, Lupin, Mylan, Orient, Sawai, Zydus <sup>f,136</sup>	May 2023 (or earlier) <sup>136</sup>
<i>Mozobil</i> (Genzyme)	Plerixafor	Zydus	July 2023 (or earlier <sup>e</sup> ) <sup>176</sup>
<i>Xyrem</i> (Jazz)	Sodium oxybate	Amneal, Ohm, Par, <sup>h,92</sup> Ranbaxy, <sup>f,143</sup> Roxane (West-Ward), Sun, <sup>f,153</sup> Wockhardt <sup>f,143</sup>	July 2023 (or earlier) (will be authorized generic) <sup>7</sup>
<i>Myrbetriq</i> (Astellas)	Mirabegron	Aurobindo, Lupin, Sawai, Zydus	November 2023 (or earlier <sup>d</sup> ) <sup>99</sup>

More . . .



<b>Brand<sup>a</sup> (Manufacturer)</b>	<b>Generic Name</b>	<b>Generic Manufacturer(s)<sup>b,1</sup></b>	<b>Anticipated Availability<sup>c</sup></b>
<i>Victoza</i> (Novo Nordisk)	Liraglutide	Teva	December 2023 (or earlier) <sup>108</sup>
<i>Gralise</i> (Depomed)	Gabapentin	Incepta, <sup>f,98</sup> Teva, Zydus, <sup>f,98</sup>	January 2024 (or earlier) <sup>62,98</sup>
<i>Isentress</i> (Merck)	Raltegravir tablet	Hetero	May 2024 <sup>24</sup>
<i>Xarelto</i> (Janssen)	Rivaroxaban	Aurobindo, <sup>150</sup> Princeton	August 2024
<i>Bepreve</i> (Bausch)	Bepotastine ophthalmic solution 1.5%	Apotex, <sup>8</sup> Micro Labs, Sandoz	September 2024 (or earlier <sup>e</sup> )
<i>Brilinta</i> (AstraZeneca)	Ticagrelor	Alembic, Alkem, Amneal, Beijing Tide, HEC Pharm, Hisun Pharm, Micro Labs, Princeton, Sandoz, Teva	October 2024 <sup>10</sup>
<i>Abilify</i> (Otsuka)	Aripiprazole orally disintegrating tablets 20 mg, 30 mg	Sun, Teva, Zydus	December 2024 (or earlier <sup>e</sup> ) <sup>86</sup>
<i>Fentora</i> (Cephalon [Teva])	Fentanyl citrate buccal tablet	Impax, <sup>f,57</sup> Mylan, Sandoz, <sup>f,106</sup>	December 2024 (or earlier <sup>e</sup> ) <sup>57</sup>
<i>Qsymia</i> (Vivus)	Phentermine/Topiramate extended-release capsule	Dr. Reddy's, <sup>f,46</sup> Teva <sup>f,41</sup>	December 2024 (or earlier) <sup>41</sup>
<i>Namzaric</i> (Forest)	Donepezil/Memantine	Amneal, Macleods	January 2025 <sup>160</sup>
<i>Nucynta</i> (Depomed)	Tapentadol tablet	Tablet: Alkem, Rhodes, Roxane, Teva Oral solution: Teva	June 2025 <sup>59</sup>
<i>Nucynta ER</i> (Depomed)	Tapentadol extended-release tablet	Teva, West-ward	June 2025 <sup>59</sup>
<i>Ravicti</i> (Horizon)	Glycerol phenylbutyrate liquid	Par	July 2025 (or earlier) <sup>119</sup>
<i>Rytary</i> (Amneal)	Levodopa/carbidopa	Teva <sup>f,166</sup>	July 2025 (or earlier) <sup>166</sup>
<i>Prolensa</i> (Bausch and Lomb)	Bromfenac 0.07% ophthalmic solution	Perrigo	September 2025 (or earlier <sup>e</sup> ) <sup>42,71</sup>

More . . .

<b>Brand<sup>a</sup> (Manufacturer)</b>	<b>Generic Name</b>	<b>Generic Manufacturer(s)<sup>b,1</sup></b>	<b>Anticipated Availability<sup>c</sup></b>
<i>Complera</i> (Gilead)	Emtricitabine, Rilpivirine, Tenofovir	Mylan	December 2025 (or earlier <sup>d</sup> ) <sup>21</sup>
<i>Xeljanz</i> (PF Prism)	Tofacitinib	Micro Labs, Princeton	December 2025 (or earlier <sup>d</sup> ) <sup>73</sup>
<i>Sprycel</i> (Bristol-Myers Squibb)	Dasatinib	Apotex	March 2026 (or earlier <sup>e</sup> ) <sup>152</sup>
<i>Natazia</i> (Bayer)	Dienogest/estradiol valerate	Lupin ( <i>Nudovra</i> ), Teva	May 2026 <sup>22</sup>
<i>Aplenzin</i> (Valeant)	Bupropion hydrobromide extended-release tablet	Paddock, <sup>h,105</sup> Par, <sup>f,83</sup> Teva	June 2026 (or earlier <sup>e</sup> ) <sup>38,83</sup>
<i>Nuedexta</i> (Avanir)	Dextromethorphan/Quinidine	Impax, <sup>f,116</sup> Par, Sandoz, <sup>f,103</sup> Teva, Wockhardt <sup>f,85</sup>	July 2026 (or earlier) <sup>54,85,103</sup>
<i>Brisdelle</i> (Noven)	Paroxetine mesylate 7.5 mg capsule	Princeton, Teva	August 2026 <sup>9</sup>
<i>Dymista</i> (Meda)	Azelastine and fluticasone nasal spray	Apotex, Perrigo, <sup>f,113</sup> Teva	August 2026 (or earlier <sup>e</sup> ) <sup>113</sup>
<i>Gilenya</i> (Novartis)	Fingolimod	Accord, Alkem, Aurobindo, Biocon, Bionpharma, Ezra, First Time US Generics, Glenmark, HEC, MSN, Par, Strides Pharma, Teva, Torrent, Zydus	2027 (or earlier) <sup>102</sup>
<i>Kyprolis</i> (Onyx)	Carfilzomib	Apotex, Natco (Breckenridge), Qilu	2027 (or earlier) <sup>51</sup>
<i>Dexilant</i> (Takeda)	Dexlansoprazole	Impax, <sup>f,104</sup> Par, TWi <sup>f,93</sup>	February 2027 (or earlier <sup>e</sup> ) <sup>135</sup>
<i>Aveed</i> (Endo)	Testosterone undecanoate	Paddock	March 2027
<i>Dyloject</i> (Javelin)	Diclofenac injection	Mylan	March 2027 (or earlier <sup>e</sup> ) <sup>89</sup>
<i>Oxtellar</i> (Supernus)	Oxcarbazepine extended-release tablet	Teva, TWi	April 2027
<i>Tradjenta</i> (Boehringer Ingelheim)	Linagliptin	Accord, Aurobindo, Dr. Reddy's, <sup>h,120</sup> HEC, InvaGen, MSN, Mylan, Princeton, Teva, Zydus	May 2027 (or earlier <sup>d</sup> ) <sup>120</sup>

More . . .

<b>Brand<sup>a</sup> (Manufacturer)</b>	<b>Generic Name</b>	<b>Generic Manufacturer(s)<sup>b,1</sup></b>	<b>Anticipated Availability<sup>c</sup></b>
<i>Lumigan</i> (Allergan)	Bimatoprost ophthalmic solution 0.01%	Alembic, Apotex, Gland, Hi-Tech, Lupin, <sup>f,123</sup> Sandoz, Teva <sup>f,123</sup>	June 2027 <sup>123</sup>
<i>Prezista</i> (Janssen)	Darunavir tablet	Cipla, Hetero, Lupin, Mylan, Teva	June 2027 (or earlier <sup>e</sup> ) <sup>79</sup>
<i>Picato</i> (Leo Pharma)	Ingenol mebutate 0.015% gel	Perrigo, Teva	July 2027 (or earlier <sup>e</sup> ) <sup>147</sup>
<i>Xtandi</i> (Astellas)	Enzalutamide	Eugia, Teva	August 2027 (or earlier, but not before July 2021) <sup>126</sup>
<i>Sklice</i> (Arbor)	Ivermectin lotion 0.5%	Taro	October 2027 (or earlier <sup>d</sup> ) <sup>139</sup>
<i>Fanapt</i> (Vanda)	Iloperidone	Alembic, Hikma, <sup>f,157</sup> Inventia, Taro	November 2027 <sup>157</sup>
<i>Nexavar</i> (Bayer)	Sorafenib	Mylan, Yabao	December 2027 (or earlier <sup>e</sup> ) <sup>137,141</sup>
<i>Oracea</i> (Galderma)	Doxycycline 40 mg capsule	Amneal, Lupin, Mylan	December 2027 <sup>110</sup>
<i>Enbrel</i> (Amgen)	Etanercept	Samsung Bioepis (biosimilar; <i>Eticovo</i> <sup>i</sup> ), Sandoz (biosimilar; <i>Erelzi</i> <sup>i</sup> )	2028 (or earlier) <sup>35</sup>
<i>Otezla</i> (Celgene)	Apremilast	Amneal, Annora	February 2028 (or earlier <sup>d</sup> ) <sup>87</sup>
<i>Promacta</i> (Novartis)	Eltrombopag	Hetero, Teva	February 2028 (or earlier <sup>d</sup> ) <sup>21</sup>
<i>Tecfidera</i> (Biogen)	Dimethyl fumarate	Accord, Alkem, Amneal, Aurobindo, Cipla, Hetero, Lupin, MSN, Sawai, Shilpa, Sun, Torrent, TWI, Zydus	February 2028 (or earlier <sup>d</sup> ) <sup>21</sup>
<i>Nesina</i> (Takeda)	Alogliptin	Alembic, Hetero, MSN, Sunshine Lake, Torrent	June 2028 <sup>173</sup> (authorized generic available)
<i>Prepopik</i> (Ferring)	Citric acid, magnesium oxide, sodium picosulfate	Par	October 2028 <sup>91</sup>
<i>Onglyza</i> (Bristol-Myers Squibb)	Saxagliptin	Amneal, Aurobindo, Glenmark, Par, Teva, Wockhardt <sup>h,133</sup>	November 2028 (or earlier <sup>e</sup> ) <sup>69</sup>

More . . .

<b>Brand<sup>a</sup> (Manufacturer)</b>	<b>Generic Name</b>	<b>Generic Manufacturer(s)<sup>b,1</sup></b>	<b>Anticipated Availability<sup>c</sup></b>
<i>Pennsaid</i> (HZNP)	Diclofenac sodium 2% solution	Amneal, Lupin, Perrigo (Paddock), Taro, Teva	January 2029 (or earlier) <sup>66</sup>
<i>Colcrys</i> (Takeda)	Colchicine	Alkem, Amneal, Par, Teva, Zydus	February 2029 (or earlier <sup>e</sup> ) <sup>64</sup> (authorized generic available)
<i>Finacea Foam</i> (Bayer)	Azelaic acid foam	Perrigo, Teva	February 2029 (or earlier <sup>e</sup> ) <sup>28</sup>
<i>Lo Loestrin Fe</i> (Actavis)	Ethinyl estradiol/Norethindrone acetate/Ferrous fumarate	Glenmark, Mylan	February 2029
<i>Multaq</i> (Sanofi-Aventis)	Dronedarone	Alkem, Amneal, Glenmark, Teva, Unimark <sup>h,134</sup>	April 2029 (or earlier <sup>e</sup> ) <sup>56</sup>
<i>Kazano</i> (Takeda)	Alogliptin/metformin	Torrent	May 2029 (or earlier <sup>d</sup> ) <sup>21</sup> (authorized generic available)
<i>Onexton</i> (Dow)	Benzoyl peroxide 3.75%/ Clindamycin phosphate 1.2%	Perrigo, <sup>f,12</sup> Taro, Teva	August 2029 (or earlier <sup>e</sup> ) <sup>12</sup>
<i>Evotaz</i> (Gilead)	Atazanavir/cobicistat	Mylan	September 2029 (or earlier <sup>d</sup> ) <sup>138</sup>
<i>Savella</i> (Forest)	Milnacipran	Amneal, Apotex, <sup>f,14</sup> First Time US Generics, <sup>h,140</sup> Glenmark, Hetero, <sup>h,132</sup> Lupin, Macleods, Mylan, Par, Ranbaxy (Sun), <sup>h,132</sup> Sandoz, <sup>h,52</sup> USPharma Windlas	September 2029 (or earlier <sup>e</sup> ) <sup>127</sup> (may be authorized generic) <sup>127</sup>
<i>Tykerb</i> (Novartis)	Lapatinib	Natco	September 2029 (or earlier <sup>d</sup> ) <sup>21</sup>
<i>Travatan Z</i> (Alcon)	Travoprost 0.004% ophthalmic solution	Apotex, Argentum, <sup>f,128</sup> Mylan, Par	October 2029
<i>Tivicay</i> (Viiiv)	Dolutegravir	Aurobindo, Cipla, Laurus, Mylan	December 2029 (or earlier <sup>d</sup> ) <sup>21</sup>
<i>Triumeq</i> (Viiiv)	Abacavir, dolutegravir, lamivudine	Laurus	December 2029 (or as early as October 2027 <sup>d</sup> ) <sup>96</sup>
<i>Zyclara</i> (Medicis)	Imiquimod cream 3.75%	Taro	December 2029 (or earlier <sup>e</sup> ) <sup>17</sup>
<i>Contrave</i> (Orexigen)	Bupropion/Naltrexone sustained release tablet	Teva <sup>f,114</sup>	February 2030 <sup>114</sup>

More . . .

<b>Brand<sup>a</sup> (Manufacturer)</b>	<b>Generic Name</b>	<b>Generic Manufacturer(s)<sup>b,1</sup></b>	<b>Anticipated Availability<sup>c</sup></b>
<i>Jentaduetto</i> (Boehringer Ingelheim)	Linagliptin/Metformin	Accord, Dr. Reddy's, <sup>h,159</sup> HEC Pharm, Intas, <sup>h,50</sup> MSN Labs, Mylan, Zydus	June 2030 (or earlier <sup>e</sup> ) <sup>168</sup>
<i>Sernivo</i> (Encore)	Betamethasone dipropionate 0.05% spray	Perrigo	August 2030 (or earlier <sup>e</sup> ) <sup>15</sup>
<i>Inlyta</i> (PF Prism CV)	Axitinib	Apotex, Teva	December 2030 (or earlier <sup>d</sup> ) <sup>21</sup>
<i>Relistor</i> (Salix)	Methylnaltrexone 12 mg/0.6 mL subcutaneous injection	Mylan, Teva <sup>f,76</sup>	December 2030
<i>Eliquis</i> (Bristol-Myers Squibb)	Apixaban	Accord, <sup>h,163</sup> Aurobindo, Breckenridge, Dr. Reddy's, <sup>h,163</sup> Lupin, Micro Labs, Mylan, Sunshine, Torrent, others	February 2031 (or earlier <sup>d</sup> ) <sup>45</sup>
<i>Quillivant XR</i> (Nextwave)	Methylphenidate extended-release suspension	Teva	February 2031 (or earlier <sup>d</sup> ) <sup>27</sup>
<i>Teflaro</i> (Allergan)	Ceftaroline	Apotex	February 2031 (or earlier <sup>e</sup> ) <sup>68</sup>
<i>Gelnique</i> (Allergan)	Oxybutynin 10% gel	Par	March 2031 (or earlier <sup>e</sup> ) <sup>32</sup>
<i>Treanda</i> (Cephalon)	Bendamustine 25 mg/vial, 100 mg/vial (solution)	Wockhardt	April 2031 (or earlier <sup>e</sup> ) <sup>16</sup>
<i>Giazo</i> (Valeant)	Balsalazide 1.1 g tablet	Apotex, <sup>h,129</sup> Lupin, Mylan, Par	June 2031 (or earlier <sup>e</sup> ) <sup>75</sup>
<i>Mirvaso</i> (Galderma)	Brimonidine tartrate gel	Perrigo	June 2031 (or earlier <sup>d</sup> ) <sup>53</sup>
<i>Sovaldi</i> (Gilead)	Sofosbuvir tablets	Natco, <sup>h,51</sup> Teva <sup>f</sup>	June 2031 (or earlier <sup>e</sup> ) <sup>10</sup>
<i>Trintellix</i> (Takeda)	Vortioxetine	Alkem	June 2031 (or earlier <sup>d</sup> ) <sup>21</sup>
<i>Fetzima</i> (Allergan)	Levomilnacipran	Amneal	May 2032
<i>Pazeo</i> (Novartis)	Olopatadine 0.7% ophthalmic solution	Apotex	May 2032 (or earlier <sup>e</sup> ) <sup>172</sup>

More. . .

<b>Brand<sup>a</sup> (Manufacturer)</b>	<b>Generic Name</b>	<b>Generic Manufacturer(s)<sup>b,1</sup></b>	<b>Anticipated Availability<sup>c</sup></b>
<i>Aptiom</i> (Sunovion)	Eslicarbazepine	Alkem	August 2032 (or earlier <sup>d</sup> ) <sup>21</sup>
<i>Zubsolv</i> (Orexo)	Buprenorphine/Naloxone sublingual tablet	Teva <sup>f,84</sup>	September 2032 <sup>84</sup>
<i>Naftin</i> (Sebela)	Naftifine 2% gel	Taro	January 2033 (or earlier <sup>e</sup> ) <sup>76</sup>
<i>Bendeka</i> (Eagle)	Bendamustine 100 mg/4 mL	Apotex, Fresenius Kabi, Mylan, <sup>h,43</sup> Slayback <sup>h,169</sup>	March 2033 (or earlier <sup>d</sup> )
<i>Qudexy XR</i> (Upsher Smith)	Topiramate extended-release capsule	Glenmark	March 2033 (or earlier <sup>e</sup> ) <sup>90</sup>
<i>Ultravate</i> (Sun)	Halobetasol 0.05% lotion	Perrigo	June 2033 (or earlier <sup>d</sup> ) <sup>21</sup>
<i>Mitigare</i> (Hikma)	Colchicine	Par	August 2033 (or earlier <sup>e</sup> ) <sup>70</sup>
<i>Aczone</i> (Aqua)	Dapsone 7.5%	Taro	November 2033 (or earlier <sup>d</sup> ) <sup>21</sup>
<i>Omidria</i> (Omeros)	Ketorolac/phenylephrine ocular solution	Lupin	April 2034 (or earlier <sup>e</sup> ) <sup>19</sup>
<i>Zohydro</i> (Pernix)	Hydrocodone extended-release capsule	Alvogen, Teva	September 2034 <sup>109</sup>
<i>Narcan</i> (Emergent BioSolutions)	Naloxone nasal spray	Teva	March 2035 (or earlier <sup>d</sup> ) <sup>158</sup>
<i>Bunavail</i> (BioDelivery)	Buprenorphine/naloxone buccal film	Teva	April 2035 (or earlier <sup>e</sup> ) <sup>144</sup>
<i>Korlym</i> (Corcept)	Mifepristone	Teva	August 2038 (or earlier <sup>d</sup> ) <sup>40</sup>
<i>Alocril</i> (Allergan)	Nedocromil ophthalmic	Akorn	Uncertain <sup>g</sup>
<i>AzaSite</i> (InSite Vision)	Azithromycin 1% ophthalmic solution	Mylan, <sup>f,13</sup> Sandoz	Uncertain <sup>g</sup>
<i>Capastat</i> (Akorn)	Capreomycin	Hisun, Mylan	Uncertain <sup>g</sup>

More . . .

Brand <sup>a</sup> (Manufacturer)	Generic Name	Generic Manufacturer(s) <sup>b,1</sup>	Anticipated Availability <sup>c</sup>
<i>Dyclone</i> (AstraZeneca)	Dyclonine ( <i>Dyclopro</i> )	Novocol	Uncertain <sup>g</sup>
<i>Exelon</i> (Novartis)	Rivastigmine oral solution	Ranbaxy (Sun)	Uncertain <sup>g</sup> (brand discontinued)
<i>Helidac</i> (Casper)	Bismuth subsalicylate, metronidazole, tetracycline	Ailex	Uncertain <sup>g</sup> (brand discontinued)
<i>Iquix</i> (Santen)	Levofloxacin ophthalmic solution 1.5%	Micro Labs	Uncertain <sup>g</sup> (brand discontinued)
<i>Khedezla</i> (Osmotica)	Desvenlafaxine	Anchen	Uncertain <sup>g</sup> (brand discontinued)
<i>Liptruzet</i> (Merck)	Atorvastatin/Ezetimibe	Teva	Uncertain <sup>g</sup> (brand discontinued)
<i>ProAir HFA</i> (Teva)	Albuterol	Lupin, <sup>f,37</sup> Perrigo <sup>f,34</sup>	Uncertain (authorized generics available)
<i>Prograf</i> (Astellas)	Tacrolimus injection	Hospira	Uncertain <sup>g</sup>
<i>Vituz</i> (Cypress)	Hydrocodone bitartrate/ chlorpheniramine maleate	Acella	Uncertain <sup>g</sup>

- This list is not all-inclusive.
- Current through August 2019. These are manufacturers with either approval or tentative approval to market the generic version of the drug unless otherwise noted. For drugs already available, manufacturers with tentative approval are not listed.
- Generic availability is subject to change as a result of litigations and patent exclusivities.
- Patent challenged; availability may be sooner than patent expiration date.
- Generic manufacturer has settled patent litigation with the brand manufacturer, but settlement details unknown. Availability likely sooner than patent expiration date.
- Generic manufacturer has not received approval or tentative approval from the FDA, but has challenged the patent(s), and has either settled patent litigation with the brand manufacturer, or the patent(s) was/were upheld.
- Patents have expired; however, generics are not yet available.
- Generic manufacturer has not received approval or tentative approval from the FDA, but has filed patent challenge.
- A biosimilar is not a generic. Biosimilars and their reference product are complex biologic medicines that originate in living organisms. A biosimilar is not the exact duplicate of the reference biologic, but is very similar and is expected to have the same efficacy and safety for its approved indications.<sup>60</sup>

*More . . .*

Users of this resource are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication.

**Project Leader in preparation of this clinical resource (350932):** *Melanie Cupp, Pharm.D., BCPS*

## References

1. Drugs@FDA. FDA approved drug products. <http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm>. (Accessed August 31, 2019).
2. Anon. Novartis and Breckenridge drop cancer drug dispute. October 8, 2018. <https://www.lifesciencesipreview.com/news/novartis-and-breckenridge-drop-cancer-drug-dispute-3047>. (Accessed August 12, 2019).
3. Kass D. Mylan Pradaxa generic delayed in Boehringer patent deal. January 26, 2018. <https://www.law360.com/articles/1006299/mylan-pradaxa-generic-delayed-in-boehringer-patent-deal>. (Accessed July 25, 2019).
4. Food and Drug Administration. Tentative ANDA approval letter. Cipla generic *Emtriva*. March 29, 2011. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2011/091168s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2011/091168s000ltr.pdf). (Accessed July 25, 2019).
5. Vergauwen W. Delaware court backs UCB drug patent, shares jump. August 15, 2016. [http://www.reuters.com/article/us-ucb-sa-ruling-idUSKCN10Q001?feedType=RSS&feedName=healthNews&utm\\_source=feedburner&utm\\_medium=feed&utm\\_campaign=Feed%3A+reuters%2FhealthNews+%28Reuters+Health+News%29](http://www.reuters.com/article/us-ucb-sa-ruling-idUSKCN10Q001?feedType=RSS&feedName=healthNews&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+reuters%2FhealthNews+%28Reuters+Health+News%29). (Accessed July 25, 2019).
6. Food and Drug Administration. ANDA approval letter. Lupin generic *Moxeza*. May 8, 2015. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2015/204079Orig1s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2015/204079Orig1s000ltr.pdf). (Accessed July 23, 2019).
7. House D. Jazz settles *Xyrem* patent dispute with Amneal Pharma; shares up 2% after hours. October 11, 2018. <https://seekingalpha.com/news/3396868-jazz-settles-xyrem-patent-dispute-amneal-pharma-shares-2-percent-hours>. (Accessed July 27, 2019).
8. FDA. ANDA approval letter. Apotex generic *Bepreve*. March 5, 2019. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2019/206066Orig1s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2019/206066Orig1s000ltr.pdf). (Accessed August 20, 2019).
9. Anon. In re Sebela patent litigation. October 20, 2017. <http://www.robinskaplan.com/resources/newsletters/generically-speaking-hatch-waxman-bulletin/generically-speaking-fall-2017/in-re-sebela-patent-litigation>. (Accessed August 12, 2019).
10. Robins Kaplan LLP. ANDA litigation settlements. Winter 2019. <https://www.robinskaplan.com/resources/newsletters/generically-speaking-hatch-waxman-bulletin/generically-speaking-winter-2019/anda-litigation-settlements>. (Accessed July 27, 2019).
11. Patrick M. *Toviaz* expected to report stable revenues in 2016. October 21, 2016. <http://marketrealist.com/2016/10/toviaz-expected-report-stable-revenues-2016/>. (Accessed July 22, 2019).
12. Anon. Perrigo announces patent litigation settlement for the generic version of *Onexton* gel. <https://www.prnewswire.com/news-releases/perrigo-announces-patent-litigation-settlement-for-the-generic-version-of-onexton-gel-300543948.html>. (Accessed August 20, 2019).
13. Anon. InSite Vision (ISV) announces settlement of patent infringement lawsuit against Mylan Pharmaceuticals, Inc. (MYL). March 17, 2015. <http://www.biospace.com/News/insite-vision-announces-settlement-of-patent/369017>. (Accessed September 4, 2019).
14. Gurrieri V. Apotex exits Forest's patent suit over generic *Savella*. January 21, 2016. <https://www.law360.com/articles/748930/apotex-exits-forest-s-patent-suit-over-generic-savella>. (Accessed August 14, 2019).
15. Anon. Perrigo announces tentative FDA approval for the generic version of *Sernivo* spray, 0.05%. April 4, 2019. <https://investor.perrigo.com/2019-04-04-Perrigo-Announces-Tentative-FDA-Approval-For-The-Generic-Version-Of-Sernivo-R-Spray-0-05>. (Accessed August 14, 2019).
16. FDA. ANDA tentative approval letter. Wockhardt generic *Treanda*. June 12, 2017. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2017/207149Orig1s000TAltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2017/207149Orig1s000TAltr.pdf). (Accessed July 22, 2019).
17. FDA. Tentative ANDA approval letter. Taro generic *Zyclara* 3.75%. July 31, 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2018/205971Orig1s000TAltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2018/205971Orig1s000TAltr.pdf). (Accessed August 14, 2019).
18. Levy S. Teva releases limited doses of generic *EpiPen*. November 27, 2018. <https://www.drugstorenews.com/pharmacy/teva-releases-limited-doses-of-generic-epipen/>. (Accessed July 22, 2019).
19. FDA. ANDA approval letter. Lupin generic *Omidria*. July 1, 2019. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2019/210183Orig1s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2019/210183Orig1s000ltr.pdf). (Accessed August 17, 2019).
20. Levy S. Gilead's *Truvada* to see generic launch in September 2020. May 10, 2019. <https://www.drugstorenews.com/pharmacy/gileads->

More . . .



- truvada-to-see-generic-launch-in-september-2020/. (Accessed July 24, 2019).
21. FDA. Paragraph IV patent certifications. August 17, 2019. <https://www.fda.gov/media/82686/download>. (Accessed August 29, 2019).
  22. United States District Court for the District of Delaware. Bayer vs Watson. <https://www.bartlitbeck.com/assets/htmldocuments/12cv1726%20mem%20opinion.pdf>. (Accessed August 12, 2019).
  23. Grover N. Celgene settles U.S. patent litigation for top seller *Revlimid*. December 22, 2015. <http://www.reuters.com/article/us-celgene-revlimid-idUSKBN0U52DO20151222>. (Accessed July 25, 2019).
  24. Corporate Pharmacy Services. Upcoming generic drugs. [http://corporatepharmacy.com/page/upcoming\\_generic\\_drugs](http://corporatepharmacy.com/page/upcoming_generic_drugs). (Accessed July 22, 2019).
  25. Guillen E, Maffeo Z. When might generic *Truvada* be available for PrEP in the US? March 16, 2015. <http://www.ethantheblog.info/?p=50>. (Accessed July 24, 2019).
  26. Anon. Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for *Cyltezo* (adalimumab-adbm), a biosimilar to *Humira*, for the treatment of multiple chronic inflammatory diseases. August 29, 2017. <https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-pharmaceuticals-inc-receives-fda-approval-cyltezo-adalimumab>. (Accessed July 26, 2019).
  27. Robins Kaplan LLP. Tris Pharma Inc. v. Actavis Labs. Fl. Inc. November 20, 2018. <https://www.robinskaplan.com/resources/newsletters/generically-speaking-hatch-waxman-bulletin/generically-speaking-winter-2019/tris-pharma-inc-v-actavis-labs-fl-inc>. (Accessed July 27, 2019).
  28. Anon. Perrigo announces patent litigation settlement for the generic version of *Finacea* foam, 15%. April 2, 2019. <https://investor.perrigo.com/2019-04-02-Perrigo-Announces-Patent-Litigation-Settlement-For-The-Generic-Version-Of-Finacea-R-Foam-15>. (Accessed August 14, 2019).
  29. FDA. Tentative ANDA approval letter. Par generic Afinitor. June 9, 2017. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2017/207934Orig1s000TAltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2017/207934Orig1s000TAltr.pdf). (Accessed August 12, 2019).
  30. Wolfe J, Erman M. U.S. judge in Texas invalidates Allergan patents on *Restasis*. October 16, 2017. <http://www.reuters.com/article/us-allergan-patents/u-s-judge-in-texas-invalidates-allergan-patents-on-restasis-idUSKBN1CL2KE>. (Accessed July 22, 2019).
  31. Perrigo announces FDA approval of the generic version of *Ofirmev* acetaminophen injection. June 16, 2016. <http://www.prnewswire.com/news-releases/perrigo-announces-fda-approval-of-the-generic-version-of-ofirmev-acetaminophen-injection-300286159.html>. (Accessed July 24, 2019).
  32. Food and Drug Administration. ANDA approval letter. Par generic *Gelnique*. May 31, 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2018/207329Orig1s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2018/207329Orig1s000ltr.pdf). (Accessed August 20, 2019).
  33. Anon. USFDA approves Mylan-Biocon's biosimilar for cancer drug *Herceptin*. December 2, 2017. <http://www.thehindubusinessline.com/companies/usfda-approves-mylanbiocons-biosimilar-for-cancer-drug-herceptin/article9979931.ece>. (Accessed July 22, 2019).
  34. Alexander A. Teva reaches settlement in *ProAir HFA* patent case. June 20, 2014. <http://www.drugstorenews.com/article/teva-reaches-settlement-proair-hfa-patent-case>. (Accessed August 17, 2019).
  35. Peterson C. Biosimilars in the US: more approvals but not access. January 10, 2019. <http://lab.express-scripts.com/lab/insights/drug-options/biosimilars-in-the-us-more-approvals-but-not-access>. (Accessed August 14, 2019).
  36. Anon. Horizon Pharma announces settlement of *Rayos* (prednisone) delayed-release tablets patent litigation with Actavis Laboratories FL Inc. October 2, 2015. <https://www.biospace.com/News/horizon-pharma-announces-settlement-of-rayosr/393695>. (Accessed July 26, 2019).
  37. Palmer E. FDA rejects Perrigo knockoff of Teva's *ProAir* inhaler for third time. May 14, 2018. <https://www.fiercepharma.com/pharma/fda-rejects-perrigo-knock-off-teva-s-proair-inhaler-for-third-time>. (Accessed August 17, 2019).
  38. Coe E. Valeant ends fight with Par over generic antidepressant. December 9, 2011. <https://www.law360.com/articles/292066/valeant-ends-fight-with-par-over-generic-antidepressant>. (Accessed August 12, 2019).
  39. Anon. Somaxon Pharmaceuticals announces settlement of *Silenor* patent litigation with Actavis. February 5, 2013. <http://www.globenewswire.com/news-release/2013/02/05/521096/10020662/en/Somaxon-Pharmaceuticals-Announces-Settlement-of-Silenor-Patent-Litigation-With-Actavis.html>. (Accessed July 22, 2019).
  40. FDA. Tentative ANDA approval letter. Teva generic *Korlym*. October 12, 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2018/211436Orig1s000TAltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2018/211436Orig1s000TAltr.pdf). (Accessed August 16, 2019).
  41. Russell A. Vivus, Inc. (NASDAQ:VVUS) settles with Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA) on *Qsymia*. July 7, 2017. <https://marketexclusive.com/vivus-inc-nasdaqvvus-settles-teva-pharmaceutical-industries-ltd-adr-nyseteva-anti-obesity-drug-qsymia/2017/07/>. (Accessed July 28, 2019).
  42. Anon. Perrigo (PRGO) received tentative FDA approval for generic *Prolensa* ophthalmic solution 0.07%. January 3, 2018. <https://www.streetinsider.com/Corporate+News/Perri>

More . . .

- go+%28PRGO%29+Receives+Tentative+FDA+Approval+For+Generic+Prolensa+Ophthalmic+Solution+0.07%25/13646440.html. (Accessed July 28, 2019).
43. House DW. Teva and Eagle Pharma file new Bendeka patent infringement suit against generic competitors Mylan and Fresenius, October 16, 2018. <https://seekingalpha.com/news/3397699-teva-eagle-pharma-file-new-bendeka-patent-infringement-suit-generic-competitors-mylan>. (Accessed August 16, 2019).
  44. United States District Court. District of New Jersey. Boehringer Ingelheim Pharma GMBH & Co. KG, Boehringer Ingelheim International GMBH, and Boehringer Ingelheim Pharmaceuticals, Inc vs Hetero USA, Inc., Hetero Labs LTD. Unit-III, and Hetero Labs LTD. Complaint for patent infringement. April 26, 2016. <http://patentdocs.typepad.com/files/bi-v-hetero.pdf>. (Accessed July 25, 2019).
  45. FDA. Tentative ANDA approval. Aurobindo generic *Eliquis*. June 28, 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/appletter/2018/210026Orig1s000TAItr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/210026Orig1s000TAItr.pdf). (Accessed August 15, 2019).
  46. Anon. Dr. Reddy's settles patent row with Vivus on weight management drug. August 31, 2017. <http://www.livemint.com/Companies/qoctaOJXv23g8nHRsDXfDM/Dr-Reddys-settles-patent-row-with-Vivus-on-weight-manageme.html>. (Accessed July 28, 2019).
  47. Anon. BioMarin-Dr. Reddy's agree to settle *Kuvan* patent litigation. September 21, 2015. <https://finance.yahoo.com/news/biomarin-dr-reddys-agree-settle-182506681.html>. (Accessed July 24, 2019).
  48. Anon. Eisai and Glenmark reach settlement over generic version of *Banzel* (rufinamide). April 30, 2015. <http://www.prnewswire.com/news-releases/eisai-and-glenmark-reach-settlement-over-generic-version-of-banzel-rufinamide-300075151.html>. (Accessed July 26, 2019).
  49. Anon. Lawsuit over generic *Chantix* version filed by Pfizer. September 3, 2010. <http://www.aboutlawsuits.com/generic-chantix-lawsuit-filed-by-pfizer-12564/>. (Accessed July 23, 2019).
  50. Oslick S. Court Report. Boehringer Ingelheim Pharmaceuticals, Inc. et al. v. Intas Pharmaceuticals, Ltd., et al. November 15, 2015. <http://www.patentdocs.org/2015/week47/>. (Accessed August 14, 2019).
  51. Anon. Natco announces USFDA filing for sofosbuvir tablets, 400 mg. March 1, 2018. <http://www.natcopharma.co.in/about/news/>. (Accessed August 16, 2019).
  52. Oslick S. Court Report. Forest Laboratories Inc. et al. v. Sandoz Inc. November 17, 2013. [http://www.patentdocs.org/new\\_biotech\\_cases/page/10/](http://www.patentdocs.org/new_biotech_cases/page/10/). (Accessed August 14, 2019).
  53. Anon. Perrigo announces tentative FDA approval for generic version of *Suprep* oral solution and confirms patent challenge for generic version of *Mirvaso* gel. August 23, 2016. <http://www.prnewswire.com/news-releases/perrigo-announces-tentative-fda-approval-for-generic-version-of-suprep-oral-solution-and-confirms-patent-challenge-for-generic-version-of-mirvaso-gel-300316991.html>. (Accessed August 15, 2019).
  54. Anon. Avanir Pharmaceuticals announces settlement of *Nuedexta* patent litigation with Actavis. September 3, 2013. <http://www.avanir.com/press/avanir-pharmaceuticals-announces-settlement-nuedexta-patent-litigation-actavis>. (Accessed August 12, 2019).
  55. Bechtel J. Federal circuit upholds Shire's patents for ADHD drug. October 1, 2015. <http://www.fdanews.com/articles/173337-federal-circuit-upholds-shires-patents-for-adhd-drug>. (Accessed July 27, 2019).
  56. Food and Drug Administration. Tentative ANDA approval letter. Alkem generic *Multaq*. December 31, 2015. [https://www.accessdata.fda.gov/drugsatfda\\_docs/appletter/2015/205895Orig1s000TAItr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/205895Orig1s000TAItr.pdf). (Accessed August 14, 2019).
  57. Anon. Cephalon, Impax settle suit over *Fentora* generic. July 23, 2013. <http://maxval-ip.blogspot.com/2013/07/cephalon-impax-settle-suit-over-fentora.html>. (Accessed July 28, 2019).
  58. FDA. Tentative ANDA approval letter. BPI Labs generic *Jevtana*. May 22, 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/appletter/2018/207735Orig1s000Itr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/207735Orig1s000Itr.pdf). (Accessed July 25, 2019).
  59. Lee S. Depomed gets patent win over generic *Nucynta* drugmakers. September 30, 2016. <https://www.law360.com/articles/847206/depomed-gets-patent-win-over-generic-nucynta-drugmakers>. (Accessed July 22, 2019).
  60. FDA. Biosimilars: more treatment choices and innovation. October 23, 2017. <http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm436399.htm>. (Accessed January 12, 2019).
  61. Anon. Teva settles patent litigation with AstraZeneca allowing Teva to commercialize its generic version of *Byetta* (exenatide injection) in the United States. June 23, 2016. [https://www.tevapharm.com/news/teva\\_settles\\_patent\\_litigation\\_with\\_astrazeneca\\_allowing\\_teva\\_to\\_commercialize\\_its\\_generic\\_version\\_of\\_byetta\\_exenatide\\_injection\\_in\\_the\\_united\\_states\\_06\\_16.aspx](https://www.tevapharm.com/news/teva_settles_patent_litigation_with_astrazeneca_allowing_teva_to_commercialize_its_generic_version_of_byetta_exenatide_injection_in_the_united_states_06_16.aspx). (Accessed July 22, 2019).
  62. Anon. Depomed, Actavis settle *Gralise* ANDA patent infringement litigation. April 15, 2015. <http://www.pharmabiz.com/NewsDetails.aspx?aid=87759&sid=2>. (Accessed July 28, 2019).
  63. United States District Court for the District of Delaware. Pfizer vs Mylan. Memorandum. August 9, 2017. <https://law.justia.com/cases/federal/district-courts/delaware/dedce/1:2015cv00079/56529/89/>. (Accessed July 22, 2019).

More . . .

64. Coe E. Takeda's gout drug IP case paused after deal with Watson. January 12, 2016. <https://www.law360.com/articles/745275/takeda-s-gout-drug-ip-case-paused-after-deal-with-watson>. (Accessed August 14, 2019).
65. Food and Drug Administration. ANDA tentative approval letter. Strides Pharma generic *Edurant*. January 15, 2015. [http://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2015/205302Orig1s000TAltr.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/apletter/2015/205302Orig1s000TAltr.pdf). (Accessed July 27, 2019).
66. Anon. Horizon Pharma plc announces settlement of *Pennsaid* 2% patent litigation with Perrigo Company plc. May 8, 2015. <http://finance.yahoo.com/news/horizon-pharma-plc-announces-settlement-100000275.html>. (Accessed August 14, 2019).
67. Anon. Forest Laboratories, Inc. announces settlement of *Bystolic* patent litigation. November 7, 2013. <https://www.businesswire.com/news/home/20131107005213/en/Forest-Laboratories-Announces-Settlement-BYSTOLIC-Patent-Litigation>. (Accessed July 25, 2019).
68. FDA. Tentative ANDA approval letter. Apotex generic *Teflaro*. January 30, 2019. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2019/208075Orig1s000TAltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2019/208075Orig1s000TAltr.pdf). (Accessed June 27, 2019).
69. FDA. Tentative ANDA approval letter. Teva generic *Onglyza*. July 10, 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2018/206020Orig1s000TAltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2018/206020Orig1s000TAltr.pdf). (Accessed July 27, 2019).
70. FDA. ANDA approval letter. Par generic *Mitigare*. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2018/208678Orig1s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2018/208678Orig1s000ltr.pdf). (Accessed August 16, 2019).
71. United States District Court for the District of Delaware. Senju Pharmaceutical Co., Ltd., Bausch & Lomb Incorporated and Bausch & Lomb Pharma Holdings Corp. vs Paddock Laboratories, LLC, L. Perrigo Company, and Perrigo Company. Complaint for patent infringement. January 26, 2015. <http://patentdocs.typepad.com/files/senju-v-paddock.pdf>. (Accessed July 28, 2019).
72. Kass D. Takeda, AstraZeneca sue Apotex over generic COPD drug. December 8, 2015. <https://www.law360.com/articles/735478/takeda-astrazeneca-sue-apotex-over-generic-copd-drug>. (Accessed July 22, 2019).
73. FDA. Tentative ANDA approval letter. Prinston generic *Xeljanz*. September 25, 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2018/209923Orig1s000TAltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2018/209923Orig1s000TAltr.pdf). (Accessed August 15, 2019).
74. FDA. ANDA approval letter. Taro generic *Ferriprox*. February 2, 2019. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2019/208800Orig1s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2019/208800Orig1s000ltr.pdf). (Accessed July 24, 2019).
75. Food and Drug Administration. ANDA approval letter. Par generic *Giazo*. September 8, 2015. [http://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2015/206336Orig1s000ltr.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/apletter/2015/206336Orig1s000ltr.pdf). (Accessed August 15, 2019).
76. FDA. ANDA approval letter. Taro generic *Naftin* 2% gel. April 10, 2019. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2019/208201Orig1s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2019/208201Orig1s000ltr.pdf). (Accessed August 18, 2019).
77. Brachmann S. Horizon Pharma patents covering *Vimovo* arthritis pain relief treatment have validity upheld at district court and PTAB. July 12, 2017. <http://www.ipwatchdog.com/2017/07/12/horizon-pharma-patents-covering-vimovo-arthritis-pain-relief-treatment-validity-upheld/id=85356/>. (Accessed July 27, 2019).
78. Anon. Orexo settles *Abstral* patent litigation with Actavis. October 27, 2015. <https://www.businesswire.com/news/home/20151027005764/en/Orexo-Settles-Abstral-Patent-Litigation-Actavis>. (Accessed July 22, 2019).
79. Food and Drug Administration. ANDA approval letter. Teva generic *Prezista*. November 21, 2017. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2017/202118Orig1s000ApprovandTAltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2017/202118Orig1s000ApprovandTAltr.pdf). (Accessed August 14, 2019).
80. Wilson D. Novartis, Eisai sue rivals over planned *Banzel* generics. July 25, 2013. <http://www.law360.com/articles/459945/novartis-eisai-sue-rivals-over-planned-banzel-generics>. (Accessed July 26, 2019).
81. Food and Drug Administration. Tentative ANDA approval letter. Apotex generic *Mycamine*. April 20, 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2018/208366Orig1s000TAltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2018/208366Orig1s000TAltr.pdf). (Accessed August 20, 2019).
82. Wilson D. Pfizer targets Wockhardt in generic *Toviaz* suit. August 5, 2013. <http://www.law360.com/articles/462536/pfizer-targets-wockhardt-in-generic-toviaz-suit>. (Accessed July 22, 2019).
83. Robins Kaplan LLP. ANDA litigation settlements. 2011/2012. <http://www.robinskaplan.com/resources/newsletters/generically-speaking-hatch-waxman-bulletin/generically-speaking-winter-2011-2012/anda-litigation-settlements>. (Accessed August 12, 2018).
84. Kachakov S. Orexo wins appeal against Actavis on *Zubsolv* patent in the U.S. September 10, 2018. <http://www.ourfinancedaily.com/orexo-wins-appeal-against-actavis-on-zubsolv-patent-in-the-us/>. (Accessed August 16, 2019).
85. Anon. Avanir Pharmaceuticals announces settlement of *Nuedexta* patent litigation with Wockhardt. September 6, 2013. <http://www.prnewswire.com/news-releases/avanir-pharmaceuticals-announces-settlement-of-nuedexta-patent-litigation-with-wockhardt-222703741.html>. (Accessed August 12, 2019).

More. . .

86. FDA. ANDA approval letter. Zydus generic *Abilify* orally disintegrating tablets. August 28, 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2018/090165Orig1s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2018/090165Orig1s000ltr.pdf). (Accessed July 28, 2019).
87. FDA. Tentative ANDA approval letter. Amneal generic *Otezla*. July 19, 2019. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2019/211782Orig1s000TAltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2019/211782Orig1s000TAltr.pdf). (Accessed August 19, 2019).
88. Anon. Cipher announces settlement in patent litigation for *Absorica*. October 5, 2015. <http://www.pnewswire.com/news-releases/cipher-announces-settlement-in-patent-litigation-for-absorica-530622611.html>. (Accessed July 24, 2019).
89. FDA. ANDA approval letter. Mylan generic *Dyloject*. June 18, 2019. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2019/208786Orig1s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2019/208786Orig1s000ltr.pdf). (Accessed August 13, 2019).
90. FDA. Tentative ANDA approval letter. Glenmark generic *Qudexy XR*. January 22, 2019. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2019/210278Orig1s000TAltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2019/210278Orig1s000TAltr.pdf). (Accessed August 16, 2019).
91. Raymond N. Judge says Par's planned *Prepopik* generic infringes Ferring patents. July 11, 2017. <http://www.reuters.com/article/ip-ferring-idUSL1N1K3025>. (Accessed August 14, 2019).
92. United States District Court, District of New Jersey. Jazz vs. Par. Complaint for patent infringement. October 19, 2015. <https://patentdocs.typepad.com/files/jazz-v-par-5.pdf>. (Accessed July 27, 2019).
93. Anon. TWi announces settlement with Takeda on *Dexilant* litigation. April 27, 2015. <http://www.pnewswire.com/news-releases/twi-announces-settlement-with-takeda-on-dexilantr-litigation-300072295.html>. (Accessed August 13, 2019).
94. FDA. ANDA approval letter. Teva generic *Aptensio XR*. December 13, 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2018/208861Orig1s000TAltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2018/208861Orig1s000TAltr.pdf). (Accessed July 22, 2019).
95. Anon. Depomed settles *Zipsor* patent litigation with Watson Laboratories. June 4, 2015. <http://www.pharmabiz.com/NewsDetails.aspx?aid=88666&sid=2>. (Accessed July 25, 2019).
96. FDA. Tentative ANDA approval letter. Laurus generic *Triumeq*. March 7, 2019. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2019/210899Orig1s000TAltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2019/210899Orig1s000TAltr.pdf). (Accessed August 14, 2019).
97. Anon. Impax challenges Toviax patent-analyst blog. July 5, 2013. <https://www.nasdaq.com/article/impax-challenges-toviaz-patent-analyst-blog-cm257767>. (Accessed July 26, 2019).
98. Anon. Depomed, Inc. announces settlements with two *Gralise* ANDA filers. April 14, 2014. <http://www.biospace.com/News/depomed-inc-announces-settlements-with-two/330024/source=MoreNews>. (Accessed July 28, 2019).
99. FDA. Tentative ANDA approval letter. Sawai generic *Myrbetriq*. September 20, 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2018/209446Orig1s000TAltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2018/209446Orig1s000TAltr.pdf). (Accessed July 27, 2019).
100. Babu AJ. Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod. January 18, 2019. <https://www.reuters.com/article/us-merck-co-fda-samsung-bioepis/samsung-bioepis-biosimilar-to-roches-herceptin-wins-fda-nod-idUSKCN1PC2I9>. (Accessed July 26, 2019).
101. Food and Drug Administration. Tentative ANDA approval letter. Aurobindo generic *Kaletra*. March 10, 2009. [https://www.accessdata.fda.gov/drugsatfda\\_docs/apletter/2009/090471s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/apletter/2009/090471s000ltr.pdf). (Accessed July 24, 2019).
102. Miller J. Novartis wins *Gilenya* reprieve as judge blocks generics, for now. June 25, 2019. <https://www.reuters.com/article/us-novartis-gilenya/novartis-wins-gilenya-reprieve-as-judge-blocks-generics-for-now-idUSKCN1TQ1EO>. (Accessed July 12, 2019).
103. Anon. Avanir Pharmaceuticals announces settlement of *Nuedexta* patent litigation with Sandoz. August 14, 2013. <https://www.avanir.com/press/avanir-pharmaceuticals-announces-settlement-nuedexta-patent-litigation-sandoz>. (Accessed August 12, 2019).
104. Lawson A. Takeda triumphs in suits to block generic *Dexilant*. November 4, 2013. <http://www.law360.com/articles/485773/takeda-triumphs-in-suits-to-block-generic-dexilant>. (Accessed August 13, 2019).
105. Grande A. Biovail hits Paddock with 2<sup>nd</sup> suit over *Aplenzin* ANDA. April 16, 2010. <http://www.law360.com/articles/162439/biovail-hits-paddock-with-2nd-suit-over-aplenzin-anda>. (Accessed August 12, 2019).
106. Anon. Cephalon Inc. v. Sandoz, Inc. April 9, 2012. <http://www.robinskaplan.com/resources/newsletters/generically-speaking-hatch-waxman-bulletin/generically-speaking-spring-2012/cephalon-inc-v-sandoz-inc>. (Accessed July 28, 2019).
107. Anon. Teva announces favorable court ruling in *Treanda* (bendamustine hydrochloride) patent infringement litigation. June 10, 2016. [http://www.tevapharm.com/news/teva\\_announces\\_favorable\\_court\\_ruling\\_in\\_treanda\\_bendamustine\\_hydrochloride\\_patent\\_infringement\\_litigation\\_06\\_16.aspx](http://www.tevapharm.com/news/teva_announces_favorable_court_ruling_in_treanda_bendamustine_hydrochloride_patent_infringement_litigation_06_16.aspx). (Accessed July 22, 2019).
108. Anon. Novo Nordisk settles US patent litigation case on *Victoza* (liraglutide) with Teva. March 20, 2019. <https://www.pharmaceutical-business-review.com/news/novo-nordisk-settles-us-patent>

More. . .

- litigation-case-on-victoza-liraglutide-with-teva/. (Accessed July 27, 2019).
109. Anon. Pernix Therapeutics prevails in *Zohydro ER* ANDA litigation. February 23, 2017. <https://globenewswire.com/news-release/2017/02/23/926958/0/en/Pernix-Therapeutics-Prevails-in-Zohydro-ER-ANDA-Litigation.html>. (Accessed August 16, 2019).
  110. Anon. Research Foundation of State University of New York v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2013). August 9, 2013. <https://www.jdsupra.com/legalnews/research-foundation-of-state-university-55072/>. (Accessed August 14, 2019).
  111. Anon. Glenmark Pharma gets US FDA approval for bendamustine HCl and two oral contraceptives. March 28, 2016. <http://pharmabiz.com/NewsDetails.aspx?aid=94258&sid=2>. (Accessed July 22, 2019).
  112. Mathias T. FDA approves Pfizer's biosimilar to Roche's *Herceptin*. March 11, 2019. <https://www.reuters.com/article/us-pfizer-fda/fda-approves-pfizers-biosimilar-to-roches-herceptin-idUSKBN1QS2L0>. (Accessed September 4, 2019).
  113. Anon. Perrigo announces settlement of generic version of *Dymista* nasal spray patent litigation. July 17, 2017. <http://perrigo.investorroom.com/2017-07-17-Perrigo-Announces-Settlement-Of-Generic-Version-Of-Dymista-R-Nasal-Spray-Patent-Litigation>. (Accessed August 12, 2019).
  114. Langlois G. Orexigen defeats Actavis in weight loss pill battle. October 16, 2017. <https://www.lifesciencesipreview.com/news/orexigen-defeats-actavis-in-weight-loss-pill-battle-2458>. (Accessed August 14, 2019).
  115. Anon. Sucampo settles *Amitiza* patent litigation. October 10, 2014. <https://www.rdmag.com/news/2014/10/sucampo-settles-amitiza-patent-litigation>. (Accessed August 19, 2019).
  116. Lawson A. Avanir prevails over Par, Impax in *Nuedexta* patent row. May 1, 2014. <http://www.law360.com/articles/533643/avanir-prevails-over-par-impax-in-nuedexta-patent-row>. (Accessed August 12, 2019).
  117. Food and Drug Administration. ANDA approval letter. Taro generic *Epiduo Forte gel*. October 17, 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/appletter/2018/209148Orig1s000Ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/209148Orig1s000Ltr.pdf). (Accessed July 22, 2019).
  118. Anon. Supernus announces settlement with Zydus on *Trokendi XR* patent litigation. March 6, 2017. <http://ir.supernus.com/news-releases/news-release-details/supernus-announces-settlement-zydus-trokendi-xrr-patent>. (Accessed July 27, 2019).
  119. Anon. Horizon Pharma settles *Ravicti* patent dispute with Par Pharma. September 20, 2018. <https://seekingalpha.com/news/3391779-horizon-pharma-settles-ravicti-patent-dispute-par-pharma>. (Accessed July 28, 2019).
  120. United States District Court. District of New Jersey. Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, and Boehringer Ingelheim Pharma GmbH & Co. KG vs Dr. Reddy's Laboratories, LTD., Dr. Reddy's Laboratories, Inc., Princeton Pharmaceutical Inc., Solco Healthcare U.S., LLC, Huahai US Inc., Zhejiang Huahai Pharmaceutical Co., LTD., InvaGen Pharmaceuticals Inc. April 28, 2016. <http://patentdocs.typepad.com/files/bi-v-drl.pdf>. (Accessed August 13, 2019).
  121. Robins Kaplan. New ANDA cases. Summer 2015. <https://www.robinskaplan.com/resources/newsletters/generically-speaking-hatch-waxman-bulletin/generically-speaking-summer-2015/new-anda-cases>. (Accessed July 25, 2019).
  122. Food and Drug Administration. Tentative ANDA approval letter. Teva generic *Fycompa*. January 17, 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/appletter/2018/209801Orig1s000TAtr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/209801Orig1s000TAtr.pdf). (Accessed July 22, 2019).
  123. Decker S. Allergan wins lawsuit against Lupin, two others over *Lumigan*. January 15, 2014. <http://www.livemint.com/Companies/jCLthTyvUREQJkbyC4in7J/Allergan-wins-lawsuit-against-Actavis-Novartis-over-Lumigan.html>. (Accessed August 13, 2019).
  124. Das S. Sun Pharma gets FDA nod for generic version of *Januvia*. April 16, 2013. <https://economictimes.indiatimes.com/industry/health-care/biotech/pharmaceuticals/sun-pharma-gets-fda-nod-for-generic-version-of-januvia/articleshow/19571542.cms>. (Accessed July 26, 2019).
  125. Anon. Takeda Pharmaceutical's patent on cancer drug *Velcade* upheld by the US Court of Appeals for the Federal District. August 8, 2017. <http://www.iiprd.com/takeda-pharmaceuticals-patent-on-cancer-drug-velcade-upheld-by-the-us-court-of-appeals-for-the-federal-circuit/>. (Accessed July 25, 2019).
  126. FDA. Tentative ANDA approval letter. Teva generic *Xtandi*. March 11, 2019. [https://www.accessdata.fda.gov/drugsatfda\\_docs/appletter/2019/209614Orig1s000TA\\_ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/209614Orig1s000TA_ltr.pdf). (Accessed August 16, 2019).
  127. Jacob S. Glenmark settles patent war over *Savella*. December 21, 2015. <http://www.livemint.com/Companies/OYBtDHxTabNvlp3RYOkCCI/Glenmark-settles-patent-war-over-Savella.html>. (Accessed August 14, 2019).
  128. Anon. *Travatan Z* patent survives IPR: a lesson in successfully arguing hindsight bias. September 27, 2018. <https://www.oblon.com/publications/travatan-z-patent-survives-ipr-a-lesson-in-successfully-arguing-hindsight-bias/>. (Accessed August 14, 2019).
  129. Kass D. Valeant hits Apotex with patent suit over colitis drug. October 1, 2015.

More . . .





- <https://www.law360.com/articles/709788/valeant-hits-apotex-with-patent-suit-over-colitis-drug>. (Accessed August 15, 2019).
130. Anon. Forest Labs., LLC v. Sigmapharm Labs., LLC. July 14, 2017. <https://www.jdsupra.com/legalnews/forest-labs-llc-v-sigmapharm-labs-llc-98432/>. (Accessed July 24, 2019).
131. Anon. Sumitomo Dainippon Pharma announces resolution of disputes under consolidated infringement lawsuit regarding ANDAs for *Latuda* in the U.S. November 27, 2018. <https://www.ds-pharma.com/ir/news/pdf/ene20181127.pdf>. (Accessed July 27, 2019)
132. Atkin E. Forest sues Mylan, others to block generic *Savella*. September 24, 2013. <https://www.law360.com/articles/475117/forest-sues-mylan-others-to-block-generic-savella>. (Accessed August 14, 2019).
133. United States District Court for the District of Delaware. AstraZeneca AB vs Wockhardt Bio Ag and Wockhardt USA LLC, Complaint. May 23, 2014. <http://patentdocs.typepad.com/files/az-v-wockhardt-1.pdf>. (Accessed July 27, 2019).
134. Siegel D. Sanofi sues to block Unimark's generic *Multaq*. July 7, 2014. <https://www.law360.com/articles/554796/sanofi-sues-to-block-unimark-s-generic-multaq>. (Accessed August 14, 2019).
135. FDA. ANDA approval letter. Par generic *Dexilant*. April 19, 2017. [https://www.accessdata.fda.gov/drugsatfda\\_docs/appletter/2017/202294Orig1s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/202294Orig1s000ltr.pdf). (Accessed August 13, 2019).
136. Anon. Zydus announces settlement with Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc. and Nissan Chemical Industries, Ltd. on *Livalo* (pitavastatin calcium) tablets. January 17, 2017. [http://www.zydususa.com/Press%20Releases/2017/January\\_17\\_\\_\\_Zydus\\_Announces\\_Settlement\\_on\\_Livalo\\_R\\_Pitavastatin\\_Calcium\\_Tablets.pdf](http://www.zydususa.com/Press%20Releases/2017/January_17___Zydus_Announces_Settlement_on_Livalo_R_Pitavastatin_Calcium_Tablets.pdf). (Accessed July 27, 2019).
137. Anon. Bayer and Mylan put generic dispute to rest. October 30, 2017. <https://www.lifesciencesipreview.com/news/bayer-and-mylan-put-generic-dispute-to-rest-2488>. (Accessed August 14, 2019).
138. FDA. Tentative ANDA approval. Mylan generic *Evotaz*. March 27, 2019. [https://www.accessdata.fda.gov/drugsatfda\\_docs/appletter/2019/211124Orig1s000TA\\_ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/211124Orig1s000TA_ltr.pdf). (Accessed August 14, 2019).
139. Food and Drug Administration. Tentative ANDA approval. Taro generic *Sklice* lotion 0.5%. June 29, 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/appletter/2018/210720Orig1s000TA\\_ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/210720Orig1s000TA_ltr.pdf). (Accessed August 14, 2019).
140. Anon. Forest Laboratories, Inc. files additional lawsuit against First Time US Generics LLC for infringement. October 2, 2013. <https://www.aol.com/article/finance/2013/10/02/forest-laboratories-inc-files-additional-lawsuit-a/20736298/>. (Accessed August 14, 2019).
141. Oslik S. Court report. February 8, 2015. <https://www.patentdocs.org/2015/week7/>. (Accessed July 25, 2019).
142. United States District Court for the District of Delaware. Actavis Elizabeth LLC, vs Novartis Pharmaceuticals Corporation. July 13, 2016. <http://patentdocs.typepad.com/files/actavis-v-novartis.pdf>. (Accessed July 22, 2019).
143. Reeves A. Jazz Pharma rises as competitive position grows stronger. May 11, 2016. <http://www.investors.com/news/technology/jazz-pharma-rises-as-competitive-position-grows-stronger/>. (Accessed May 8, 2019).
144. Food and Drug Administration. Tentative ANDA approval. Teva generic *Bunavail*. June 15, 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/appletter/2018/209831Orig1s000TA\\_ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/209831Orig1s000TA_ltr.pdf). (Accessed August 16, 2019).
145. Knobbe Martens, Eisai Co., Ltd., et al. v. Lupin Ltd., et al., Case Nos. 13-civ-1279 and 13-civ-1281 (2015). <https://www.knobbe.com/attorneys/carol-pitzel-cruz/cases-articles-speeches-seminars>. (Accessed July 26, 2019).
146. Babu AJ. AbbVie settles *Humira* biosimilar dispute with Fresenius Kabi. October 18, 2018. <https://www.reuters.com/article/us-abbvie-fresenius-humira/abbvie-settles-humira-biosimilar-dispute-with-fresenius-kabi-idUSKCN1MS24Q>. (Accessed July 27, 2019).
147. Anon. Perrigo announces patent litigation settlement for the generic version of *Picato* gel. September 28, 2018. <https://finance.yahoo.com/news/perrigo-announces-patent-litigation-settlement-130000503.html>. (Accessed August 14, 2019).
148. Robins Kaplan. New ANDA cases. Summer 2016. <https://www.robinskaplan.com/resources/newsletters/generically-speaking-hatch-waxman-bulletin/generically-speaking-summer-2016/copy-of-new-anda-cases>. (Accessed August 12, 2019).
149. Anon. Spectrum Pharmaceuticals settles *Folotyn* (pralatrexate injection) ANDA patent litigation. July 13, 2016. <http://www.businesswire.com/news/home/20160713005453/en/Spectrum-Pharmaceuticals-Settles-FOLOTYN%C2%AE-pralatrexate-injection-ANDA>. (Accessed July 26, 2019).
150. Food and Drug Administration. Tentative ANDA approval. Aurobindo generic *Xarelto*. June 22, 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/appletter/2018/208544Orig1s000TA\\_ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208544Orig1s000TA_ltr.pdf). (Accessed July 28, 2019).
151. Oslick S. Patent Docs. Court report. January 5, 2015. <http://www.patentdocs.org/2015/01/04/>. (Accessed July 25, 2019).
152. Food and Drug Administration. ANDA approval letter. Apotex generic *Sprycel*. June 10, 2016. [http://www.accessdata.fda.gov/drugsatfda\\_docs/appletter/2016/202103Orig1s000ltr.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/202103Orig1s000ltr.pdf). (Accessed July 28, 2019).

More . . .

153. Penton K. Jazz makes deal in *Xyrem* IP fight with Ranbaxy, Sun, Ohm. May 13, 2016. <http://www.law360.com/articles/796247/jazz-makes-deal-in-xyrem-ip-fight-with-ranbaxy-sun-ohm>. (Accessed July 27, 2019).
154. Orexo AB, vs Mylan Pharmaceuticals Inc. and Mylan Inc. June 30, 2011. <https://www.patentdocs.org/2011/07/cou-1/comments/>. (Accessed August 20, 2019).
155. Orexo. Interim report January-June 2015. <http://feed.ne.cision.com/wpyfs/00/00/00/00/00/2E/89/30/wkr0006.pdf>. (Accessed August 20, 2019).
156. Anon. Strides Shasun receives USFDA tentative approval for roflumilast tablets. June 1, 2016. [http://www.strides.com/pdf/pressrelease/2016/usfda\\_tentative\\_approval\\_for\\_roflumilast\\_tablets.pdf](http://www.strides.com/pdf/pressrelease/2016/usfda_tentative_approval_for_roflumilast_tablets.pdf). (Accessed July 22, 2019).
157. Anon. Vanda patents found valid and infringed in *Fanapt* ANDA litigation. August 25, 2016. <http://www.pnewswire.com/news-releases/vanda-patents-found-valid-and-infringed-in-fanapt-anda-litigation-300318458.html>. (Accessed August 14, 2019).
158. FDA. Approval letter. Teva generic *Narcan*. [https://www.accessdata.fda.gov/drugsatfda\\_docs/appletter/2019/209522Orig1s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/209522Orig1s000ltr.pdf). April 19, 2019. (Accessed August 16, 2019).
159. Oslick S. Court report. May 18, 2016. [http://www.patentdocs.org/new\\_biotech\\_cases/](http://www.patentdocs.org/new_biotech_cases/). (Accessed August 14, 2019).
160. Kuber S. Allergan, Adamas settle patent lawsuit with Amneal. August 31, 2016. <http://www.reuters.com/article/us-allergan-patent-settlement-idUSKCN1161WK>. (Accessed July 28, 2019).
161. Anon. BioMarin announces *Kuvan* (sapropterin dihydrochloride) patent challenge settlement. April 13, 2017. <http://investors.biomin.com/2017-04-13-BioMarin-Announces-Kuvan-R-sapropterin-dihydrochloride-Patent-Challenge-Settlement>. (Accessed July 24, 2019).
162. Mathias T. AbbVie, Samsung Bioepis in deal; *Humira* biosimilar U.S. release in 2023. April 5, 2018. <https://www.reuters.com/article/us-abbvie-biogen/abbvie-samsung-bioepis-in-deal-humira-biosimilar-u-s-release-in-2023-idUSKCN1HC1SP>. (Accessed July 27, 2019).
163. Palmer E. BMS and Pfizer file 16 *Eliquis* patent lawsuits to waylay generic makers. April 12, 2017. <https://www.fiercepharma.com/legal/bms-and-pfizer-file-16-eliquis-patent-lawsuits-to-waylay-generic-makers>. (Accessed August 15, 2019).
164. FDA. Tentative ANDA approval letter. Teva generic *Farxiga*. February 4, 2019. [https://www.accessdata.fda.gov/drugsatfda\\_docs/appletter/2019/211541Orig1s000TAltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/211541Orig1s000TAltr.pdf). (Accessed July 24, 2019).
165. Anon. Amneal announces favorable ruling regarding patent validity for *Zomig* (zolmitriptan) nasal spray. June 29, 2018. <https://investors.amneal.com/news/press-releases/press-release-details/2018/Amneal-Announces-Favorable-Ruling-Regarding-Patent-Validity-for-Zomig-zolmitriptan-Nasal-Spray/default.aspx>. (Accessed July 22, 2019).
166. Anon. Amneal announces patent litigation settlement agreement with Actavis concerning *Rytary*. June 20, 2018. <https://investors.amneal.com/news/press-releases/press-release-details/2018/Amneal-Announces-Patent-Litigation-Settlement-Agreement-with-Actavis-Concerning-Rytary/default.aspx>. (Accessed July 28, 2019).
167. Mishra M. FDA approves Novartis' copy of AbbVie bestseller *Humira*. October 31, 2018. <https://www.reuters.com/article/us-abbvie-novartis-fda/fda-approves-novartis-copy-of-abbvie-bestseller-humira-idUSKCN1N529J>. (Accessed July 27, 2019).
168. Food and Drug Administration. Tentative ANDA approval. HEC generic *Jentadueto*. May 17, 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/appletter/2018/208336Orig1s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208336Orig1s000ltr.pdf). (Accessed August 14, 2019).
169. Robins Kaplan. New ANDA cases. Fall 2017. <https://www.robinskaplan.com/resources/newsletters/generically-speaking-hatch-waxman-bulletin/generically-speaking-fall-2017/new-anda-cases>. (Accessed August 16, 2019).
170. Anon. PTAB upholds patent for Akorn glaucoma drug *Zioptan*. November 29, 2018. <https://www.law360.com/articles/1105725/ptab-upholds-patent-for-akorn-glaucoma-drug-zioptan>. (Accessed July 26, 2019).
171. Reuters staff. Mylan signs U.S. license deal on *Humira* with AbbVie. July 17, 2018. <https://www.reuters.com/article/us-abbvie-mylan/mylan-signs-u-s-license-deal-on-humira-with-abbvie-idUSKBN1K71IU>. (Accessed July 27, 2019).
172. FDA. Tentative ANDA approval letter. Apotex generic *Pazeo*. January 9, 2019. [https://www.accessdata.fda.gov/drugsatfda\\_docs/appletter/2019/209015Orig1s000TAltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/209015Orig1s000TAltr.pdf). (Accessed August 16, 2019).
173. FDA. Tentative ANDA approval letter. Hetero generic *Nesina*. August 28, 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/appletter/2018/210240Orig1s000TAltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/210240Orig1s000TAltr.pdf). (Accessed August 14, 2019).
174. Anon. Mylan sued for patent infringement over *Aubagio*. January 13, 2017. <https://www.lifesciencesipreview.com/news/mylan-sued-for-patent-infringement-over-aubagio-1976>. (Accessed July 27, 2019).
175. Food and Drug Administration. ANDA approval letter. Fresenius Kabi generic *Mycamine*. May 17, 2019. [https://www.accessdata.fda.gov/drugsatfda\\_docs/appletter/2019/207344Orig1s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/207344Orig1s000ltr.pdf). (Accessed August 18, 2019).
176. Oslick S. Patent docs. Court report. August 11, 2016. [http://www.patentdocs.org/new\\_biotech\\_cases/](http://www.patentdocs.org/new_biotech_cases/). (Accessed July 27, 2019).

More . . .

***Cite this document as follows: Clinical Resource, Anticipated Availability of First-Time Generics. Pharmacist's Letter/Prescriber's Letter. September 2019.***

   pharmacist's letter™	<i>Evidence and Recommendations You Can Trust...</i>	   prescriber's letter™
   pharmacy technician's letter™		   nurse's letter™
3120 West March Lane, Stockton, CA 95219 ~ TEL (209) 472-2240 ~ FAX (209) 472-2249 Copyright © 2019 by Therapeutic Research Center		

Subscribers to the *Letter* can get clinical resources, like this one,  
on any topic covered in any issue by going to  
[pharmacist.therapeuticresearch.com](http://pharmacist.therapeuticresearch.com) ~ [prescriber.therapeuticresearch.com](http://prescriber.therapeuticresearch.com) ~  
[pharmacytech.therapeuticresearch.com](http://pharmacytech.therapeuticresearch.com) ~ [nursesletter.therapeuticresearch.com](http://nursesletter.therapeuticresearch.com)